Top

Published in:

01-08-2012 | Clinical Study

Evaluation of brain tumors using dynamic ¹¹C-methionine-PET

Authors: Tatsuki Aki, Noriyuki Nakayama, Shingo Yonezawa, Syunsuke Takenaka, Kazuhiro Miwa, Yoshitaka Asano, Jun Shinoda, Hirohito Yano, Toru Iwama

Published in: Journal of Neuro-Oncology | Issue 1/2012

Abstract

The aim of this study is to assess whether dynamic imaging of ¹¹C-methionine (MET) uptake on positron emission tomography (PET) is useful for the differential diagnosis of brain tumor histology. Regional MET uptake in static brain PET scans from three consecutive phases (5–15, 15–25, and 25–35 min) after intravenous injection were measured in 144 patients with brain tumors. Regions of interest (ROI) were placed in the pituitary gland, confluence, choroid plexus, coronal radiation, brainstem, frontal cortex, parietal cortex, cerebellum, and brain tumors. The standard uptake value (SUV) of the ROIs in the normal brain structures and brain tumors were measured, and the mean MET SUV region/normal frontal lobe cortex uptake ratio (R/N ratio) of the normal brain structures and the maximum MET SUV tumor/normal frontal cortex uptake ratio (T/N ratio) were evaluated semi-quantitatively. There were significant dynamic declines of the mean MET R/N ratio in the normal pituitary gland and confluence; however, there were significant dynamic increases in white matter. Significant dynamic decrease of the maximum MET T/N ratio was seen in meningiomas and oligodendrocytic tumors, whereas significant dynamic increase was seen in glioblastomas and malignant lymphomas. Dynamic changes of MET uptake vary significantly with the normal brain structures and brain tumor histology. These results suggest that MET-PET may be useful in the differential diagnosis of brain tumors.

De Witte O, Goldberg I, Wikler D et al (2001) Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg 95:746–750PubMedCrossRef

Herholz K, Holzer T, Bauer B et al (1998) ¹¹C-methionine PET for differential diagnosis of low grade gliomas. Neurology 50:1316–1322PubMedCrossRef

Kato T, Shinoda J, Oka N et al (2008) Analysis of ¹¹C-methionine uptake in low grade gliomas and correlation with proliferative activity. Am J Neuroradiol 29:1867–1871PubMedCrossRef

Nariai T, Tanaka Y, Wakimoto H et al (2005) Usefulness of l-[methyl-¹¹C] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J Neurosurg 103:498–507PubMedCrossRef

Ogawa T, Inugami A, Hatazawa J et al (1996) Clinical positron emission tomography for brain tumors: comparison of fludeoxyglucose F 18 and l-methyl-¹¹C-methionine. Am J Neuroradiol 17:345–353PubMed

Ogawa T, Shihido F, Kanno I et al (1993) Cerebral glioma: evaluation with methionine PET. Radiology 186:45–53PubMed

Tovi M, Lilja A, Bergstrom M et al (1990) Delineation of gliomas with magnetic resonance imaging using Gd-DTPA in comparison with computed tomography and positron emission tomography. Acta Radiol 31:417–429PubMed

Nojiri T, Nariai T, Aoyagi M et al (2009) Contributions of biological tumor parameters to the incorporation rate of l-[methyl-¹¹C] methionine into astrocytomas and oligodendrogliomas. J Neurooncol 93:233–241PubMedCrossRef

Kato T, Shinoda J, Nakayama N et al (2008) Metabolic assessment of gliomas using ¹¹C-methionine, ¹⁸F-fluorodeoxy-glucose, and ¹¹C-choline positron-emission tomography. Am J Neuroradiol 29:1176–1182PubMedCrossRef

10.

Ribom D, Eriksson A, Hartman M et al (2001) Positron emission tomography ¹¹C-methionine and survival in patients with low-grade gliomas. Cancer 92:1541–1549PubMedCrossRef

11.

Derlon JM, Chapon F, Noel MH et al (2000) Non-invasive grading of oligodendrogliomas: correlation between in vivo metabolic pattern and histopathology. Eur J Nucl Med 27:778–787PubMedCrossRef

12.

Tsuyuguchi N, Matsuoka Y, Sunada I et al (2001) Evaluation of pleomorphic xanthoastrocytoma by use of positron emission tomography with ¹⁸F-fluorodeoxyglucose and ¹¹C-methionine tracers. Am J Neuroradiol 22:311–313PubMed

13.

Roelcke U, Radu EW, Hausmann O et al (1998) Tracer transport and metabolism in a patient with juvenile pilocytic astrocytoma: a PET study. J Neurooncol 36:279–283PubMedCrossRef

14.

Norris AM, Carrington BM, Slevin NJ (1997) Late radiation change in the CNS: MR imaging following gadolinium enhancement. Clin Radiol 52:356–362PubMedCrossRef

15.

Hustinx R, Pourdehnad M, Kaschten B et al (2005) PET imaging for differentiating recurrent brain tumor from radiation necrosis. Radiol Clin North Am 43:35–47PubMedCrossRef

16.

Hein P, Eskey C, Dunn J et al (2004) Diffusion-weighted imaging in the follow-up of treated high grade gliomas. Am J Neuroradiol 25:201–209PubMed

17.

Terakawa Y, Tsuyuguchi N, Iwai Y et al (2008) Diagnostic accuracy of ¹¹C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med 49:694–699PubMedCrossRef

18.

Jacobs A (1995) Amino acid uptake in ischemically compromised brain tissue. Stroke 26:1859–1866PubMedCrossRef

19.

Mineura K, Sasajima T, Kowada M et al (1997) Indications for differential diagnosis of nontumor central nervous system disease from tumors. A positron emission tomography study. J Neuroimaging 7:8–15PubMed

20.

Dethy S, Manto M, Kentos A et al (1995) PET findings in a brain abscess associated with a silent atrial septal defect. Clin Neurol Neurosurg 97:349–353PubMedCrossRef

21.

Kawai N, Okauchi M, Miyake K et al (2010) ¹¹C-methionine positron emission tomography in nontumorous brain lesions. No Shinkei Geka 38:985–995PubMed

22.

Kracht LW, Friese M, Herholz K et al (2003) Methyl-[¹¹C]-l-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging 30:868–873PubMedCrossRef

23.

Ishiwata K, Kubota K, Murakami M et al (1993) Re-evaluation of amino acid PET studies: can the protein synthesis rates in brain and tumor tissues be measured in vivo? J Nucl Med 34:1936–1943PubMed

24.

Moulin-Romsee G, D’Hondt E, de Groot T et al (2007) Non-invasive grading of tumor using dynamic amino acid PET imaging: dose it work for ¹¹C-methionine? Eur J Nucl Med Mol Imaging 34:2082–2087PubMedCrossRef

25.

Thompson CJ, Dagher A, Lunney DN (1986) A technique to reject scattered radiation in PET transmission scans. Proc SPIE 671:244–253

26.

Kapouleus I, Alavi A, Alves WM et al (1991) Registration of three-dimensional MR and PET images of the human brain without markers. Radiology 181:731–739

27.

Uda T, Tsuyuguchi N, Terakawa Y et al (2010) Evaluation of the accumulation of ¹¹C-methionine with standardized uptake value in the normal brain. J Nucl Med 51:219–222PubMedCrossRef

28.

Cha S, Tihan T, Crawford F et al (2005) Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas using quantitative blood-volume measurements derived from dynamic susceptibility contrast MR imaging. Am J Neuroradiol 26:266–273PubMed

29.

Aroen HJ, Gazit IE, Louis DN et al (1994) Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 191:41–51

30.

Sugihara T, Korogi Y, Koichi M et al (1998) Correlation of MR and imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. Am J Roentgenol 171:1479–1486

31.

Nyberg G, Bergstrom M, Enblad P et al (1997) PET-methionine of skull base neuromas and meningiomas. Acta Otolaryngol 117:482–489PubMedCrossRef

32.

Dowd CF, Halbach VV, Higashida RT (2003) Meningiomas: the role of preoperative angiography and embolization. Neurosurg Focus 15:E10PubMedCrossRef

33.

Utriainen M, Metsahonkala L, Salmi TT et al (2002) Metabolic characterization of childhood brain tumors: comparison of ¹⁸F-fluorodeoxyglucose and ¹¹C-methionine positron emission tomography. Cancer 95:1376–1386PubMedCrossRef

34.

Galldiks N, Kracht LW, Berthold F et al (2009) [¹¹C]-l-methionine positron emission tomography in the management of children and young adults with brain tumors. J Neurooncol 96:231–239PubMedCrossRef

Title: Evaluation of brain tumors using dynamic 11C-methionine-PET
Authors: Tatsuki Aki
Noriyuki Nakayama
Shingo Yonezawa
Syunsuke Takenaka
Kazuhiro Miwa
Yoshitaka Asano
Jun Shinoda
Hirohito Yano
Toru Iwama
Publication date: 01-08-2012
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 1/2012
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-012-0873-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Evaluation of brain tumors using dynamic ¹¹C-methionine-PET

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2012

Waiting times before initiation of radiotherapy might not affect outcomes for patients with glioblastoma: a French retrospective analysis of patients treated in the era of concomitant temozolomide and radiotherapy

Valproic acid affected the survival and invasiveness of human glioma cells through diverse mechanisms

Erratum to: Multifocal CNS infiltration of chronic lymphocytic leukemia in the form of small-cell solid metastatic lesions

Conventional MRI does not reliably distinguish radiation necrosis from tumor recurrence after stereotactic radiosurgery

Papillary tumors of the pineal region: a novel therapeutic option—stereotactic 125iodine brachytherapy

Dual contrast perfusion MRI in a single imaging session for assessment of pediatric brain tumors